Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Array Biopharma Inc patents


Recent patent applications related to Array Biopharma Inc. Array Biopharma Inc is listed as an Agent/Assignee. Note: Array Biopharma Inc may have other listings under different names/spellings. We're not affiliated with Array Biopharma Inc, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "A" | Array Biopharma Inc-related inventors


Array Biopharma, Inc.

. . ... Array Biopharma Inc

Point mutations in trk inhibitor-resistant cancer and methods relating to the same

Provided herein are methods of treating a subject having a cancer, methods of selecting a treatment for a subject having a cancer, methods of selecting a subject having a cancer for a treatment that does not include a trk inhibitor, methods of determining the likelihood that a subject having a cancer will have a positive response to a treatment with a trk inhibitor, methods of predicting the efficacy of a trk inhibitor in a subject having cancer, methods of determining a subject's risk for developing a trk inhibitor-resistant cancer, and methods of determining the presence of a trk inhibitor-resistant cancer in a subject, based on the detection of a cell from a sample from the subject that has at least one of the the point mutations in ntrk1 and/or ntrk2 and/or ntrk3.. . ... Array Biopharma Inc

Polymorphs of arry-380, a selective her2 inhibitor and pharmaceutical compositions containing them

Polymorphs of n4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-n6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine are provided herein. Processes for preparing the polymorphs and pharmaceutical composition comprising the polymorphs are also disclosed.. ... Array Biopharma Inc

Array Biopharma, Inc.

. . ... Array Biopharma Inc

Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds

Compounds useful in the synthesis of compounds for treating pain, cancer, inflammation, neurodegenerative disease or typanosoma cruzi infection in a mammal.. . ... Array Biopharma Inc

Point mutations in trk inhibitor-resistant cancer and methods relating to the same

Provided herein are methods of treating a subject having a cancer, methods of selecting a treatment for a subject having a cancer, methods of selecting a subject having a cancer for a treatment that does not include a trk inhibitor, methods of determining the likelihood that a subject having a cancer will have a positive response to a treatment with a trk inhibitor, methods of predicting the efficacy of a trk inhibitor in a subject having cancer, methods of determining a subject's risk for developing a trk inhibitor-resistant cancer, and methods of determining the presence of a trk inhibitor-resistant cancer in a subject, based on the detection of a cell from a sample from the subject that has at least one of the the point mutations in ntrk1 and/or ntrk2 and/or ntrk3.. . ... Array Biopharma Inc

Array Biopharma Inc.

. . ... Array Biopharma Inc

Kras g12c inhibitors

The present invention relates to compounds that inhibit kras g12c. In particular, the present invention relates to compounds that irreversibly inhibit the activity of kras g12c, pharmaceutical compositions comprising the compounds and methods of use therefor.. ... Array Biopharma Inc

Point mutations in trk inhibitor-resistant cancer and methods relating to the same

Provided herein are methods of treating a subject having a cancer, methods of selecting a treatment for a subject having a cancer, methods of selecting a subject having a cancer for a treatment that does not include a trk inhibitor, methods of determining the likelihood that a subject having a cancer will have a positive response to a treatment with a trk inhibitor, methods of predicting the efficacy of a trk inhibitor in a subject having cancer, methods of determining a subject's risk for developing a trk inhibitor-resistant cancer, and methods of determining the presence of a trk inhibitor-resistant cancer in a subject, based on the detection of a cell from a sample from the subject that has at least one of the point mutations in ntrk1 and/or ntrk2 and/or ntrk3.. . ... Array Biopharma Inc

Point mutations in trk inhibitor-resistant cancer and methods relating to the same

Provided herein are methods of treating a subject having a cancer, methods of selecting a treatment for a subject having a cancer, methods of selecting a subject having a cancer for a treatment that does not include a trk inhibitor, methods of determining the likelihood that a subject having a cancer will have a positive response to a treatment with a trk inhibitor, methods of predicting the efficacy of a trk inhibitor in a subject having cancer, methods of determining a subject's risk for developing a trk inhibitor-resistant cancer, and methods of determining the presence of a trk inhibitor-resistant cancer in a subject, based on the detection of a cell from a sample from the subject that has at least one of the point mutations in ntrk1 and/or ntrk2 and/or ntrk3.. . ... Array Biopharma Inc

Crystalline form of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate

A novel crystalline form of (s)—n-(5-((r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide, pharmaceutical compositions containing said crystalline form and the use of said crystalline form in the treatment of pain, cancer, inflammation, neurodegenerative disease or trypanosoma cruzi infection are disclosed. In some embodiments, the novel crystalline form comprises a stable polymorph of (s)—n-(5-((r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate. ... Array Biopharma Inc

Macrocyclic compounds as trk kinase inhibitors

Compounds of formula i: and pharmaceutically acceptable salts thereof, wherein ring a, ring b, w, m, d, r2, r2a, r3, r3a, and z are as defined herein, are inhibitors of trk kinases and are useful in the treatment of pain, cancer, inflammation, neurodegenerative diseases and certain infectious diseases.. . ... Array Biopharma Inc

Array Biopharma, Inc.

. . ... Array Biopharma Inc

Point mutations in trk inhibitor-resistant cancer and methods relating to the same

Provided herein are methods of treating a subject having a cancer, methods of selecting a treatment for a subject having a cancer, methods of selecting a subject having a cancer for a treatment that does not include a trk inhibitor, methods of determining the likelihood that a subject having a cancer will have a positive response to a treatment with a trk inhibitor, methods of predicting the efficacy of a trk inhibitor in a subject having cancer, methods of determining a subject's risk for developing a trk inhibitor-resistant cancer, and methods of determining the presence of a trk inhibitor-resistant cancer in a subject, based on the detection of a cell from a sample from the subject that has at least one of the the point mutations in ntrk1 and/or ntrk2 and/or ntrk3.. . ... Array Biopharma Inc

09/14/17 / #20170260202

Quinazoline analogs as receptor tyrosine kinase inhibitors

This invention provides compounds of formula 11:. . ... Array Biopharma Inc

09/07/17 / #this invention provides compounds of formula i

Array Biopharma, Inc.

. . ... Array Biopharma Inc

08/17/17 / #20170231963

Preparation of and formulation comprising a mek inhibitor

The present invention relates to processes for preparing 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3h-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide, processes for preparing crystallized 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3h-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide, and intermediates useful therefore. Also provided herein are pharmaceutical compositions comprising this crystallized compound.. ... Array Biopharma Inc

08/03/17 / #20170217936

Pyrrolidinyl urea, pyrrolidinyl thiourea and pyrrolidinyl guanidine compounds as trka kinase inhibitors

Compounds of formula i: or stereoisomers, tautomers, or pharmaceutically acceptable salts, or solvates or prodrugs thereof, where r1, r2, ra, rb, rc, rd, x, y, b, and ring c are as defined herein, and wherein the y—b moiety and the nh—c(═x)—nh moiety are in the trans configuration, are inhibitors of trka kinase and are useful in the treatment of diseases which can be treated with a trka kinase inhibitor such as pain, cancer, inflammation, neurodegenerative diseases and certain infectious diseases.. . ... Array Biopharma Inc

07/20/17 / #20170202837

Pharmaceutical formulations

This invention relates to solid oral pharmaceutical formulations or(s)-methyl ((4(4-(3-(5-chtoro-2-fluoro-3-(methyl-sutfonamido)phenyl)-1-isopropyl-1h-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate (compound a) and the use of these formulations for treating proliferative diseases, such as solid tumor diseases.. . ... Array Biopharma Inc

06/22/17 / #20170172988

Method of treatment using inhibitors of mitosis

Methods of treating diseases caused by cell division or that are treated by inhibiting mitosis by administering two doses of an inhibitor of mitosis between the biologically effective dose and the maximum tolerated dose in a dosing cycle that allows for the recovery or subsiding of side effects, wherein the second dose is administered 24 to 48 hours after the first dose.. . ... Array Biopharma Inc

06/15/17 / #20170165267

Crystalline form of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate

A novel crystalline form of (s)—n-(5-((r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide, pharmaceutical compositions containing said crystalline form and the use of said crystalline form in the treatment of pain, cancer, inflammation, neurodegenerative disease or trypanosoma cruzi infection are disclosed. In some embodiments, the novel crystalline form comprises a stable polymorph of (s)—n-(5-((r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate. ... Array Biopharma Inc

05/18/17 / #20170136022

Solid dispersions of a erb2 (her2) inhibitor

A solid dispersion of n4-(4-([1,2,4]triazolo[1,5-α]pyridin-7-yloxy)-3-methylphenyl)-n6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and processes for preparing the solid dispersion are provided herein. Also, a pharmaceutical composition comprising a solid dispersion of n4-(4-([1,2,4]triazolo[1,5-α]pyridin-7-yloxy)-3-methylphenyl)-n6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and uses thereof are provided herein.. ... Array Biopharma Inc

05/04/17 / #compounds of formula i:

Array Biopharma, Inc.

. . ... Array Biopharma Inc

04/27/17 / #methods for treating a disease or disorder selected from pain, cancer, inflammation, neurodegenerative disease, typanosoma cruzi infection and osteolytic disease in a mammal, which comprise administering to said mammal a therapeutically effective amount of a compound of formula i

Array Biopharma, Inc.

. . ... Array Biopharma Inc

04/27/17 / #compounds of formula i:

Array Biopharma, Inc.

. . ... Array Biopharma Inc

04/27/17 / #20170114067

Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds

Compounds useful in the synthesis of compounds for treating pain, cancer, inflammation, neurodegenerative disease or typanosoma cruzi infection in a mammal.. . ... Array Biopharma Inc

04/27/17 / #20170114059

Macrocyclic compounds as trk kinase inhibitors

Compounds of formula i: and pharmaceutically acceptable salts thereof, wherein ring a, ring b, w, m, d, r2, r2a, r3, r3a, and z are as defined herein, are inhibitors of trk kinases and are useful in the treatment of pain, cancer, inflammation, neurodegenerative diseases and certain infectious diseases.. . ... Array Biopharma Inc

04/27/17 / #20170112842

Macrocyclic compounds as trk kinase inhibitors

Compounds of formula i: and pharmaceutically acceptable salts thereof, wherein ring a, ring b, w, m, d, r2, r2a, r3, r3a, and z are as defined herein, are inhibitors of trk kinases and are useful in the treatment of pain, cancer, inflammation, neurodegenerative diseases and certain infectious diseases.. . ... Array Biopharma Inc

04/20/17 / #20170107232

Macrocyclic compounds as trk kinase inhibitors

Compounds of formula i: and pharmaceutically acceptable salts thereof, wherein ring a, ring b, w, m, d, r2, r2a r3 and r3a are as defined herein, are inhibitors of trk kinases and are useful in the treatment of pain, cancer, inflammation, neurodegenerative diseases and certain infectious diseases.. . ... Array Biopharma Inc

04/06/17 / #provided herein are compounds of the general formula i:

Array Biopharma, Inc.

. . ... Array Biopharma Inc

03/30/17 / #20170087156

1-((3s,4r)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(2-methylpyrimidin-5-yl)-1-phenyl-1h-pyrazol-5-yl)urea as a trka kinase inhibitor

Provided is compound (i) or a pharmaceutically acceptable salt thereof, which is an inhibitor of trka kinase and is useful in the treatment of diseases which can be treated with a trka kinase inhibitor such as pain, cancer, inflammation and inflammatory diseases, neurodegenerative diseases, certain infectious diseases, sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis, pelvic pain syndrome, diseases related to an imbalance of the regulation of bone remodeling, and diseases resulting from connective tissue growth factor aberrant signaling.. . ... Array Biopharma Inc

03/09/17 / #20170066733

Mitotic kinesin inhibitors and methods of use thereof

This invention relates to inhibitors of mitotic kinesins, particularly ksp, and methods for producing these inhibitors.. . ... Array Biopharma Inc

03/02/17 / #20170056375

Pharmaceutical composition

The invention concerns pharmaceutical compositions containing a hydrogen sulphate salt of 6-(4-bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3h-benzoimidazole-5-carboxylic acid (2-hydroxy-ethoxy)-amide and solvates, crystalline forms and amorphous forms thereof, to the use of said compositions as a medicament; and to processes for the preparation of said compositions.. . ... Array Biopharma Inc








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Array Biopharma Inc in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Array Biopharma Inc with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###